RET fusion partners dictate oncogenic potential in undifferentiated spindle cell sarcomas.
Qi Gui, Ying Zhang, Mei Yang et al.
✦ AI-curated · Sources linked
Case in brief
A patient presented with a spindle cell tumor containing an MYH10::RET fusion, which initially responded to anti-RET therapy. However, the tumor relapsed due to the emergence of an NTRK1 fusion. Subsequent management involved sequential targeted therapies, including third-generation inhibitors for RET and NTRK, highlighting the need for ongoing genomic monitoring to adapt treatment strategies.
Diagnostic / clinical pearl
Clinicians should recognize that different RET fusion partners can influence the aggressiveness of spindle cell tumors and may necessitate tailored therapeutic approaches.
Why it matters
This case underscores the importance of continuous genomic profiling in managing RET-rearranged tumors to identify resistance mechanisms and optimize treatment strategies.